415 related articles for article (PubMed ID: 14624476)
21. Paraoxonase and arylesterase activities in untreated dipper and non-dipper hypertensive patients.
Yildiz A; Gur M; Demirbag R; Yilmaz R; Akyol S; Aslan M; Erel O
Clin Biochem; 2008 Jul; 41(10-11):779-84. PubMed ID: 18355454
[TBL] [Abstract][Full Text] [Related]
22. Serum paraoxonase activities in hemodialyzed uremic patients: cohort study.
Juretić D; Tadijanović M; Rekić B; Simeon-Rudolf V; Reiner E; Baricić M
Croat Med J; 2001 Apr; 42(2):146-50. PubMed ID: 11259735
[TBL] [Abstract][Full Text] [Related]
23. Measurement of serum paraoxonase activity and MDA concentrations in patients suffering with oral squamous cell carcinoma.
Malik UU; Siddiqui IA; Hashim Z; Zarina S
Clin Chim Acta; 2014 Mar; 430():38-42. PubMed ID: 24389054
[TBL] [Abstract][Full Text] [Related]
24. Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment.
Sarandol A; Kirli S; Akkaya C; Ocak N; Eroz E; Sarandol E
J Psychopharmacol; 2007 Nov; 21(8):857-63. PubMed ID: 17715203
[TBL] [Abstract][Full Text] [Related]
25. Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis.
Baskol G; Demir H; Baskol M; Kilic E; Ates F; Kocer D; Muhtaroglu S
Clin Biochem; 2005 Oct; 38(10):951-5. PubMed ID: 16055108
[TBL] [Abstract][Full Text] [Related]
26. Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke.
Can Demirdöğen B; Türkanoğlu A; Bek S; Sanisoğlu Y; Demirkaya S; Vural O; Arinç E; Adali O
Clin Biochem; 2008 Jan; 41(1-2):1-9. PubMed ID: 17920578
[TBL] [Abstract][Full Text] [Related]
27. Paraoxonase and arylesterase activities in coronary artery disease.
Gur M; Aslan M; Yildiz A; Demirbag R; Yilmaz R; Selek S; Erel O; Ozdogru I
Eur J Clin Invest; 2006 Nov; 36(11):779-87. PubMed ID: 17032345
[TBL] [Abstract][Full Text] [Related]
28. Effects of long-term antidepressant treatment on oxidative status in major depressive disorder: a 24-week follow-up study.
Kotan VO; Sarandol E; Kirhan E; Ozkaya G; Kirli S
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jul; 35(5):1284-90. PubMed ID: 21515329
[TBL] [Abstract][Full Text] [Related]
29. Decreased paraoxonase and arylesterase activities in the pathogenesis of future atherosclerotic heart disease in women with gestational diabetes mellitus.
Camuzcuoglu H; Toy H; Cakir H; Celik H; Erel O
J Womens Health (Larchmt); 2009 Sep; 18(9):1435-9. PubMed ID: 19698032
[TBL] [Abstract][Full Text] [Related]
30. Changes of serum paraoxonase (an HDL-cholesterol-associated lipophilic antioxidant) and arylesterase activities in severe preeclamptic women.
Kumru S; Aydin S; Gursu MF; Ozcan Z
Eur J Obstet Gynecol Reprod Biol; 2004 Jun; 114(2):177-81. PubMed ID: 15140512
[TBL] [Abstract][Full Text] [Related]
31. Alpha-tocopherol supplementation prevents the exercise-induced reduction of serum paraoxonase 1/arylesterase activities in healthy individuals.
Tsakiris S; Karikas GA; Parthimos T; Tsakiris T; Bakogiannis C; Schulpis KH
Eur J Clin Nutr; 2009 Feb; 63(2):215-21. PubMed ID: 17882129
[TBL] [Abstract][Full Text] [Related]
32. Decreased paraoxonase 1 activity and increased oxidative stress in low lead-exposed workers.
Permpongpaiboon T; Nagila A; Pidetcha P; Tuangmungsakulchai K; Tantrarongroj S; Porntadavity S
Hum Exp Toxicol; 2011 Sep; 30(9):1196-203. PubMed ID: 21296834
[TBL] [Abstract][Full Text] [Related]
33. Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALS.
Wills AM; Landers JE; Zhang H; Richter RJ; Caraganis AJ; Cudkowicz ME; Furlong CE; Brown RH
Neurology; 2008 Mar; 70(12):929-34. PubMed ID: 18347314
[TBL] [Abstract][Full Text] [Related]
34. Early effects of sodium valproate monotherapy on serum paraoxonase/arylesterase activities.
Karikas GA; Schulpis KH; Bartzeliotou A; Regoutas S; Thanopoulou C; Papaevangelou V; Giannoulia-Karantana A; Papassotiriou I; Fytou-Pallikari A
Scand J Clin Lab Invest; 2009; 69(1):31-5. PubMed ID: 19016076
[TBL] [Abstract][Full Text] [Related]
35. Paraoxonase activity in glomerulonephritic patients.
Gullulu M; Kahvecioglu S; Dirican M; Akdag I; Ocak N; Demircan C; Dilek K; Ersoy A; Yavuz M; Yurtkuran M
Ren Fail; 2007; 29(4):433-9. PubMed ID: 17497465
[TBL] [Abstract][Full Text] [Related]
36. Synergistic effects of BuChE non-UU phenotype and paraoxonase (PON1) 55 M allele on the risk of systemic lupus erythematosus: influence on lipid and lipoprotein metabolism and oxidative stress, preliminary report.
Bahrehmand F; Vaisi-Raygani A; Rahimi Z; Ahmadi R; Kiani A; Tavilani H; Vaisi-Raygani H; Pourmotabbed T
Lupus; 2014 Mar; 23(3):263-72. PubMed ID: 24399815
[TBL] [Abstract][Full Text] [Related]
37. Paraoxonase and arylesterase activity and total oxidative/anti-oxidative status in patients with chronic adenotonsillitis.
Koc S; Aksoy N; Bilinc H; Duygu F; Uysal IÖ; Ekinci A
Int J Pediatr Otorhinolaryngol; 2011 Nov; 75(11):1364-7. PubMed ID: 21893350
[TBL] [Abstract][Full Text] [Related]
38. Lipid peroxidation markers in adult attention deficit hyperactivity disorder: new findings for oxidative stress.
Bulut M; Selek S; Bez Y; Cemal Kaya M; Gunes M; Karababa F; Celik H; Savas HA
Psychiatry Res; 2013 Oct; 209(3):638-42. PubMed ID: 23680468
[TBL] [Abstract][Full Text] [Related]
39. Discordance in human paraoxonase-1 gene between phenotypes and genotypes in chronic kidney disease.
Paragh G; Seres I; Harangi M; Pocsai Z; Asztalos L; Locsey L; Szeles G; Kardos L; Varga E; Karpati I; Adany R
Nephron Clin Pract; 2009; 113(1):c46-53. PubMed ID: 19602899
[TBL] [Abstract][Full Text] [Related]
40. PON1 status in haemodialysis patients and the impact of hepatitis C infection.
Horoz M; Aslan M; Selek S; Koylu AO; Bolukbas C; Bolukbas FF; Celik H; Erel O
Clin Biochem; 2007 Jun; 40(9-10):609-14. PubMed ID: 17335792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
